AN2 Therapeutics, Inc. (ANTX)
3.55
-0.09
(-2.47%)
USD |
NASDAQ |
Oct 23, 16:00
3.555
0.00 (0.00%)
After-Hours: 20:00
AN2 Therapeutics EPS Diluted (Quarterly) : -0.1829 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.1829 |
| March 31, 2026 | -0.2944 |
| December 31, 2025 | -0.2869 |
| September 30, 2025 | -0.3089 |
| June 30, 2025 | -0.2142 |
| March 31, 2025 | -0.3543 |
| December 31, 2024 | -0.2517 |
| September 30, 2024 | -0.4272 |
| June 30, 2024 | -0.484 |
| March 31, 2024 | -0.5583 |
| Date | Value |
|---|---|
| December 31, 2023 | -0.5683 |
| September 30, 2023 | -0.6515 |
| June 30, 2023 | -0.8106 |
| March 31, 2023 | -0.7904 |
| December 31, 2022 | -0.6103 |
| September 30, 2022 | -0.5844 |
| June 30, 2022 | -0.5216 |
| March 31, 2022 | -0.5063 |
| December 31, 2021 | -0.5061 |
| September 30, 2021 | -0.457 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Cocrystal Pharma, Inc. | -0.2295 |
| CNBX Pharmaceuticals, Inc. | -0.0001 |
| Arvinas, Inc. | 2.578 |
| Fulcrum Therapeutics, Inc. | -0.3433 |
| Definium Therapeutics, Inc. | -1.436 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -8.185M |
| Total Expenses (Quarterly) | 8.185M |
| Enterprise Value | 50.51M |
| Earnings Yield | -30.23% |
| Normalized Earnings Yield | -30.23 |